Journal of the American College of Radiology
Volume 5, Issue 1 , Pages 45-52 , January 2008

The Impact of NSF on the Care of Patients With Kidney Disease

  • Ali Abu-Alfa, MD

      Affiliations

    • Corresponding Author InformationCorresponding author and reprints: Ali Abu-Alfa, MD, Yale School of Medicine, Department of Internal Medicine, Section of Nephrology, 330 Cedar Street, FMP 107, New Haven, CT 06510-8042

References 

  1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(suppl):S1–S266
  2. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41:1–12
  3. Coresh J, Byrd-Holt D, Astor BC, et al. Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. J Am Soc Nephrol. 2005;16:180–188
  4. DeHoratius DM, Cowper SE. Nephrogenic systemic fibrosis: an emerging threat among renal patients. Semin Dial. 2006;19:191–194
  5. Cowper SE. Nephrogenic fibrosing dermopathy. http://www.icnfdr.orgAccessed April 27, 2007
  6. Mendoza FA, Artlett CM, Sandorfi N, Latinis K, Piera-Velazquez S, Jimenez SA. Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum. 2006;35:238–249
  7. Cheng S, Abramova L, Saab G, et al. Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents—St (Louis, Missouri, 2002-2006). Morbid Mortal Weekly Rep. 2007;56:137–141
  8. USRDS Coordinating Center. USRDS 2006 report. 2006;ADR:4.1
  9. Gilliet M, Cozzio A, Burg G, Nestle FO. Successful treatment of three cases of nephrogenic fibrosing dermopathy with extracorporeal photopheresis. Br J Dermatol. 2005;152:531–536
  10. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology. 2007;243:148–157
  11. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol. 2006;17:2359–2362
  12. Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol. 2007;188:586–592
  13. Pryor JG, Poggioli G, Galaria N, et al. Nephrogenic systemic fibrosis: a clinicopathologic study of six cases. J Am Acad Dermatol. 2007;57:105–111
  14. Dharnidharka VR, Wesson SK, Fennell RS. Gadolinium and nephrogenic fibrosing dermopathy in pediatric patients. Pediatr Nephrol. 2007;22:1395
  15. Grobner T. Gadolinium—a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?. Nephrol Dial Transplant. 2006;21:1104–1108
  16. Khurana A, Runge VM, Narayanan M, Greene JF, Nickel AE. Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (Omniscan). Invest Radiol. 2007;42:139–145
  17. Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol. 2007;2:264–267
  18. Zhang H, Maki JH, Prince MR. 3D contrast-enhanced MR angiography. J Magn Reson Imaging. 2007;25:13–25
  19. Thomsen HS. Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide. Eur Radiol. 2006;16:2619–2621
  20. US Food and Drug Administration. Information for healthcare professionals: gadolinium-based contrast agents for magnetic resonance imaging scans. http://www.fda.gov/cder/drug/InfoSheets/HCP/gcca_200612HCP.htmAccessed April 7, 2007
  21. European Medicines Agency (EMEA). Gadolinium-containing MRI contrast agents and nephrogenic systemic fibrosis (NSF). http://www.ismrm.org/special/EMEA1.pdfAccessed April 7, 2007
  22. Swaminathan S, Ahmed I, McCarthy JT, et al. Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med. 2006;145:234–235
  23. Levine JM, Taylor RA, Elman LB, et al. Involvement of skeletal muscle in dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy). Muscle Nerve. 2004;30:569–577
  24. Jimenez SA, Artlett CM, Sandorfi N, et al. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum. 2004;50:2660–2666
  25. Fazeli A, Lio PA, Liu V. Nephrogenic fibrosing dermopathy: are ACE inhibitors the missing link?. Arch Dermatol. 2004;140:1401
  26. Saab G, Abu-Alfa AK. Are patients with moderate renal failure at risk for developing nephrogenic systemic fibrosis?. Radiology. 2007;244:930–931
  27. Baron PW, Cantos K, Hillebrand DJ, et al. Nephrogenic fibrosing dermopathy after liver transplantation successfully treated with plasmapheresis. Am J Dermatopathol. 2003;25:204–209
  28. Maloo M, Abt P, Kashyap R, et al. Nephrogenic systemic fibrosis among liver transplant recipients: a single institution experience and topic update. Am J Transplant. 2006;6:2212–2217
  29. Swartz RD, Crofford LJ, Phan SH, Ike RW, Su LD. Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med. 2003;114:563–572
  30. Poggio ED, Nef PC, Wang X, et al. Performance of the Cockcroft-Gault and modification of diet in renal disease equations in estimating GFR in ill hospitalized patients. Am J Kidney Dis. 2005;46:242–252
  31. Skluzacek PA, Szewc RG, Nolan CR, Riley DJ, Lee S, Pergola PE. Prediction of GFR in liver transplant candidates. Am J Kidney Dis. 2003;42:1169–1176
  32. Marckmann P, Skov L, Rossen K, Heaf JF, Thomsen HS. Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant. 2007;22:3174–3178
  33. Mackay-Wiggan JM, Cohen DJ, Hardy MA, Knobler EH, Grossman ME. Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). J Am Acad Dermatol. 2003;48:55–60
  34. Jan F, Segal JM, Dyer J, LeBoit P, Siegfried E, Frieden IJ. Nephrogenic fibrosing dermopathy: two pediatric cases. J Pediatr. 2003;143:678–681
  35. Thomsen HS, Morcos SK, Dawson P. Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)?. Clin Radiol. 2006;61:905–906
  36. Kanal E, Barkovich AJ, Bell C, et al. ACR guidance document for safe MR practices: 2007. AJR Am J Roentgenol. 2007;188:1447–1474
  37. St Peter WL, Obrador GT, Roberts TL, Collins AJ. Trends in intravenous iron use among dialysis patients in the United States (1994-2002). Am J Kidney Dis. 2005;46:650–660
  38. Hutchison AJ, Maes B, Vanwalleghem J, et al. Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study. Nephron Clin Pract. 2006;102:c61–c71
  39. Saitoh T, Hayasaka K, Tanaka Y, Kuno T, Nagura Y. Dialyzability of gadodiamide in hemodialysis patients. Radiat Med. 2006;24:445–451
  40. Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol. 1998;5:491–502
  41. Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology. 2007;242:647–649
  42. Prince MR, Erel HE, Lent RW, et al. Gadodiamide administration causes spurious hypocalcemia. Radiology. 2003;227:639–646
  43. Ueda J, Furukawa T, Yamamoto T, Sakaguchi K, Araki Y. Permeability of gadolinium-DTPA through two types of hemodialysis membrane. Invest Radiol. 1998;33:734–737
  44. Okada S, Inoue K, Kijima T, Katagiri K, Kumazaki T. Effect of the surface potential of the hemodialysis membrane and the electrical charge of the gadolinium contrast medium on dialyzability. J Nippon Med Sch. 2003;70:12–15
  45. Choyke PL, Girton ME, Vaughan EM, Frank JA, Austin HA. Clearance of gadolinium chelates by hemodialysis: an in vitro study. J Magn Reson Imaging. 1995;5:470–472
  46. Abe M, Kuno T, Takahashi Y, Nagura Y, Matsumoto K. Evaluation of the elimination and safety of gadodiamide injection in patients with hemodialysis. Nippon Jinzo Gakkai Shi. 2004;46:810–814
  47. Okada S, Katagiri K, Kumazaki T, Yokoyama H. Safety of gadolinium contrast agent in hemodialysis patients. Acta Radiol. 2001;42:339–341
  48. Krahe T, Gotz R, Lackner K, et al. Pharmacokinetics of gadolinium-DTPA in chronic renal insufficiency requiring dialysis. Rofo. 1992;156:523–526
  49. Katagiri K, Okada S, Kumazaki T, Tsuboi N. Clearance of gadolinium contrast agent by hemodialysis: in vitro and clinical studies. Nippon Igaku Hoshasen Gakkai Zasshi. 1998;58:739–744
  50. Tombach B, Bremer C, Reimer P, et al. Using highly concentrated gadobutrol as an MR contrast agent in patients also requiring hemodialysis: safety and dialysability. AJR Am J Roentgenol. 2002;178:105–109
  51. Haustein J, Niendorf HP, Krestin G, et al. Renal tolerance of gadolinium-DTPA/dimeglumine in patients with chronic renal failure. Invest Radiol. 1992;27:153–156
  52. Normann PT, Joffe P, Martinsen I, Thomsen HS. Quantification of gadodiamide as Gd in serum, peritoneal dialysate and faeces by inductively coupled plasma atomic emission spectroscopy and comparative analysis by high-performance liquid chromatography. J Pharm Biomed Anal. 2000;22:939–947
  53. Van Wagoner M, Worah D. Gadodiamide injection (First human experience with the nonionic magnetic resonance imaging enhancement agent). Invest Radiol. 1993;28(suppl):S44–S48
  54. Schuhmann-Giampieri G, Krestin G. Pharmacokinetics of Gd-DTPA in patients with chronic renal failure. Invest Radiol. 1991;26:975–979
  55. Tweedle MF, Wedeking P, Kumar K. Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats. Invest Radiol. 1995;30:372–380
  56. Weinmann HJ, Laniado M, Mutzel W. Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. Physiol Chem Phys Med NMR. 1984;16:167–172
  57. McLachlan SJ, Eaton S, De Simone DN. Pharmacokinetic behavior of gadoteridol injection. Invest Radiol. 1992;27(suppl):S12–S15
  58. Swan SK, Lambrecht LJ, Townsend R, et al. Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with renal impairment. Invest Radiol. 1999;34:443–448
  59. Berg KJ, Lundby B, Reinton V, Nordal KP, Rootwelt K, Smith HJ. Gadodiamide in renal transplant patients: effects on renal function and usefulness as a glomerular filtration rate marker. Nephron. 1996;72:212–217
  60. Swan SK, Baker JF, Free R, et al. Pharmacokinetics, safety, and tolerability of gadoversetamide injection (OptiMARK) in subjects with central nervous system or liver pathology and varying degrees of renal function. J Magn Reson Imaging. 1999;9:317–321
  61. Yoshikawa K, Davies A. Safety of ProHance in special populations. Eur Radiol. 1997;7(suppl):S246–S250

PII: S1546-1440(07)00453-X

doi: 10.1016/j.jacr.2007.08.018

Journal of the American College of Radiology
Volume 5, Issue 1 , Pages 45-52 , January 2008

Article Tools

* Image Usage & Resolution